A new RNA treatment to reduce heart scarring in Duchenne muscular dystrophy
Targeting myocardial fibrosis with a novel noncoding RNA in Duchenne muscular dystrophy
A new RNA-based medicine aims to reduce heart scarring in people with Duchenne muscular dystrophy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11252176 on NIH RePORTER |
What this research studies
Researchers are developing TY4, a small chemically modified RNA inspired by molecules found in heart-cell vesicles, to reduce fibrosis (scarring) in the heart of people with Duchenne muscular dystrophy. In mouse models of DMD, TY4 showed disease-modifying effects and worked when given by mouth together with the protein casein. The team is studying how TY4 changes the behavior of immune cells called macrophages and the genes they turn on or off. If the approach continues to look promising, the work could move toward testing in people.
Who could benefit from this research
Good fit: People with Duchenne muscular dystrophy, especially those with early signs of heart involvement or at risk for cardiomyopathy, would be the most relevant candidates.
Not a fit: People without Duchenne muscular dystrophy or those with very advanced, irreversible heart failure are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, TY4 could reduce heart scarring in Duchenne muscular dystrophy and help preserve heart function.
How similar studies have performed: This is a novel class of RNA drug: related Y-RNA-derived molecules have shown benefit in animal models, but TY4 itself has so far only shown promise in mouse studies.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Rogers, Russell — Cedars-Sinai Medical Center
- Study coordinator: Rogers, Russell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.